Predictions
Dottikon ES Holding AG
Start price
Target price
Perf. (%)
€48.00
11.05.22
11.05.22
€54.00
11.05.23
11.05.23
0.00%
11.05.23
11.05.23
Could be very worthwhile Investment >20% year
Small challenges to pay loans and raise capital
Chemocentryx Inc.
Start price
Target price
Perf. (%)
€16.10
07.05.22
07.05.22
€20.00
07.05.23
07.05.23
222.26%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year
Clovis Oncology Inc.
Start price
Target price
Perf. (%)
€1.00
06.05.22
06.05.22
-
06.05.23
06.05.23
-24.17%
15.05.22
15.05.22
Risky Investment
Novavax Inc.
Start price
Target price
Perf. (%)
€55.10
03.05.22
03.05.22
€60.00
03.05.23
03.05.23
-22.67%
25.05.22
25.05.22
Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float
Zosano Pharma Corp.
Start price
Target price
Perf. (%)
€1.43
02.05.22
02.05.22
€1.00
02.05.23
02.05.23
18.02%
05.05.22
05.05.22
Could be worthwhile Investment >10% per year
Capable Management
Good culture
Growths slower than the competition
Molecular Templates Inc.
Start price
Target price
Perf. (%)
€1.56
01.05.22
01.05.22
-
01.05.23
01.05.23
-24.58%
14.05.22
14.05.22
Risky Investment
Anavex Life Sciences Corp
Start price
Target price
Perf. (%)
€8.03
01.05.22
01.05.22
-
01.05.23
01.05.23
-12.75%
24.04.23
24.04.23
Risky Investment
Higher risks for its business
High valuation
Gritstone Oncology Inc
Start price
Target price
Perf. (%)
€2.52
28.04.22
28.04.22
-
28.04.23
28.04.23
-2.36%
30.04.22
30.04.22
Risky Investment
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.37
28.04.22
28.04.22
€2.00
28.04.23
28.04.23
0.74%
03.08.22
03.08.22
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Eckert & Ziegler Strahlen- und Medizintechnik AG
Start price
Target price
Perf. (%)
€48.92
25.04.22
25.04.22
€120.00
03.02.25
03.02.25
-15.02%
07.10.24
07.10.24
Higher EBIT margin than peer group
Revenue growth >5% per year expected
EBIT growth >5% per year expected
High valuation
Myovant Sciences Ltd
Start price
Target price
Perf. (%)
€8.69
22.04.22
22.04.22
-
22.04.23
22.04.23
3.54%
30.04.22
30.04.22
Could be worthwhile Investment >10% per year
Voyager Therapeutics Inc
Start price
Target price
Perf. (%)
€6.60
21.04.22
21.04.22
-
21.04.23
21.04.23
4.15%
01.05.22
01.05.22
Risky Investment
Curis Inc.
Start price
Target price
Perf. (%)
€1.14
19.04.22
19.04.22
-
19.04.23
19.04.23
-21.19%
01.05.22
01.05.22
Risky Investment
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€5.99
19.04.22
19.04.22
-
12.04.24
12.04.24
-68.19%
12.04.24
12.04.24
Could be worthwhile Investment >10% per year
Inovio Pharma
Start price
Target price
Perf. (%)
€3.05
12.04.22
12.04.22
€1.60
12.04.23
12.04.23
-30.60%
03.08.22
03.08.22
Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Myovant Sciences Ltd
Start price
Target price
Perf. (%)
€9.86
12.04.22
12.04.22
-
12.04.23
12.04.23
-0.02%
16.04.22
16.04.22
Could be worthwhile Investment >10% per year
Corcept Therapeutics Inc.
Start price
Target price
Perf. (%)
€21.85
12.04.22
12.04.22
-
12.04.23
12.04.23
-9.84%
12.04.23
12.04.23
Novavax Inc.
Start price
Target price
Perf. (%)
€52.93
11.04.22
11.04.22
€40.00
11.04.23
11.04.23
4.10%
03.05.22
03.05.22
Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float
Affimed N.V.
Start price
Target price
Perf. (%)
€4.75
11.04.22
11.04.22
-
11.04.23
11.04.23
-41.07%
08.06.22
08.06.22
Could be worthwhile Investment >10% per year
Clovis Oncology Inc.
Start price
Target price
Perf. (%)
€2.64
06.04.22
06.04.22
€0.000
06.04.23
06.04.23
-22.00%
18.04.22
18.04.22
Could be worthwhile Investment >10% per year
Revenue decline > 20% expected
EBIT decline > 20% expected
Decining EBIT margin than peer group
Clovis Oncology Inc.
Start price
Target price
Perf. (%)
€2.64
06.04.22
06.04.22
€1.00
06.04.23
06.04.23
-22.00%
18.04.22
18.04.22
Probably not worthwhile Investment
Decining EBIT margin than peer group
overvalued
Very low/no dividend yield expected
Protalix Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€1.76
04.04.22
04.04.22
€0.000
04.04.23
04.04.23
-33.28%
18.04.22
18.04.22
EBIT decline > 20% expected
Revenue decline > 20% expected
Very low/no dividend yield expected
Sustainability is not important
Protalix Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€1.76
04.04.22
04.04.22
€0.000
04.04.23
04.04.23
-35.27%
02.06.22
02.06.22
Could be worthwhile Investment >10% per year
Revenue decline/stagnation expected
EBIT decline > 20% expected
overvalued
Clovis Oncology Inc.
Start price
Target price
Perf. (%)
€2.28
03.04.22
03.04.22
-
03.04.23
03.04.23
-98.20%
04.04.23
04.04.23
Probably not worthwhile Investment